An observational study in Bone Sarcoma and Soft Tissue Sarcoma, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Mayo Clinic · Observational
This study evaluates the effectiveness of intraoperative indocyanine green dye and fluoroscopic technology in confirming negative margins after tumor removal.
PRIMARY OBJECTIVE:
I. To evaluate the use of indocyanine green (ICG) as an intraoperative guide during bone and soft tissue sarcoma resection.
OUTLINE: This is an observational study.
Patients receive ICG infusion prior to undergoing scheduled resection and have medical records reviewed on study.
Patients with biopsy-proven bone or soft tissue sarcoma undergoing resection recruited through Mayo Clinic
Exclusion Criteria:
Patients receive ICG infusion prior to undergoing scheduled resection and have medical records reviewed on study.
Other: Non-Interventional Study
Non-interventional study
Accuracy of intraoperative ICG fluorescence compared to final pathology results
Intraoperative ICG fluorescence and deduced margins will be analyzed and compared the accuracy to final pathology margins. Negative predictive value will be calculated.
Time frame: Baseline
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mayo Clinic